POMPE-C Tool for Pulmonary Embolism Mortality
In the setting of a patient with known cancer who has been diagnosed with a pulmonary embolism, the POMPE-C can be used to estimate their mortality.
The POMPE-C Prediction Tool was risk stratifies patients diagnosed with pulmonary embolism and have active cancer.
- The POMPE-C prediction tool predicts mortality directly (at 30 days), not a risk category of mortality.
- Active cancer has been shown to be a risk factor for PE, but less so for cancer in remission.
- The POMPE-C has not been validated for incidental PE (PE found on imaging but without symptoms), though a small sample was identified and found to be low-risk overall.
- The POMPE-C may be more accurate in predicting outcome than the PESI Score in the setting of patients with active cancer.
- The POMPE-C has not yet been validated for selecting patients for outpatient management (though there is potential for future research).
- Risk stratification is a vital part of the evaluation of a patient diagnosed with PE.
- Most risk-stratification tools use cancer as a prognostic indicator, but no risk stratification tool exists for those patients with known cancer.
- Those patients that are determined to be low risk (score ≤5%) may warrant outpatient management (though this has not been validated).
Result:
Please fill out required fields.

About the Creator
Jeffrey Kline, MD, is a professor of emergency medicine and physiology and the vice chair of research at Indiana University. Among other research, he has conducted clinical studies using breath-based methods to diagnose and assess the severity of PE. He co-founded BreathQuant Medical Systems Inc to advance practical applications of 16 patents for medical devices. Dr. Kline has published over 50 manuscripts in the area of PE.
To view Dr. Jeffrey Kline's publications, visit PubMed